Cardiomyopathy-associated protein 5 (CMYA5)
Homo sapiens — UniProt Q8N3K9
Gene: CMYA5Homo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Cardiomyopathy-associated protein 5 (CMYA5) is a protein from Homo sapiens identified by UniProt accession Q8N3K9, 4069 residues long. MolForge cross-references it against 0 known binders and 125 disease associations.
- UniProt accession: Q8N3K9; gene symbol CMYA5.
- Organism: Homo sapiens.
- Length: 4069 amino acids.
- Top disease associations (Open Targets): neurodegenerative disease, PHF-tau measurement and diet measurement.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Cardiomyopathy-associated protein 5 |
|---|---|
| UniProt accession | Q8N3K9 |
| Gene | CMYA5 |
| Organism | Homo sapiens |
| Length | 4069 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (125)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.35
- PHF-tau measurement · score 0.33
- diet measurement · score 0.31
- body height · score 0.11
- Familial short QT syndrome · score 0.08
- hypertrophic cardiomyopathy · score 0.08
- Brugada syndrome · score 0.08
- Romano-Ward syndrome · score 0.08
- familial atrial fibrillation · score 0.08
- Arrhythmogenic right ventricular dysplasia · score 0.08
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q8N3K9-F15 | alphafold | PREDICTED | 56.05 | — |
| AF-Q8N3K9-F14 | alphafold | PREDICTED | 50.28 | — |
| AF-Q8N3K9-F13 | alphafold | PREDICTED | 45.17 | — |
| AF-Q8N3K9-F12 | alphafold | PREDICTED | 42.00 | — |
| AF-Q8N3K9-F11 | alphafold | PREDICTED | 40.29 | — |
| AF-Q8N3K9-F1 | alphafold | PREDICTED | 39.28 | — |
| AF-Q8N3K9-F10 | alphafold | PREDICTED | 39.02 | — |
| AF-Q8N3K9-F4 | alphafold | PREDICTED | 38.27 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q8N3K9.
Amino-acid sequence (4069 residues)
MASRDSNHAG ESFLGSDGDE EATRELETEE ESEGEEDETA AESEEEPDSR LSDQDEEGKI KQEYIISDPS FSMVTVQRED SGITWETNSS RSSTPWASEE SQTSGVCSRE GSTVNSPPGN VSFIVDEVKK VRKRTHKSKH GSPSLRRKGN RKRNSFESQD VPTNKKGSPL TSASQVLTTE KEKSYTGIYD KARKKKTTSN TPPITGAIYK EHKPLVLRPV YIGTVQYKIK MFNSVKEELI PLQFYGTLPK GYVIKEIHYR KGKDASISLE PDLDNSGSNT VSKTRKLVAQ SIEDKVKEVF PPWRGALSKG SESLTLMFSH EDQKKIYADS PLNATSALEH TVPSYSSSGR AEQGIQLRHS QSVPQQPEDE AKPHEVEPPS VTPDTPATMF LRTTKEECEL ASPGTAASEN DSSVSPSFAN EVKKEDVYSA HHSISLEAAS PGLAASTQDG LDPDQEQPDL TSIERAEPVS AKLTPTHPSV KGEKEENMLE PSISLSEPLM LEEPEKEEIE TSLPIAITPE PEDSNLVEEE IVELDYPESP LVSEKPFPPH MSPEVEHKEE ELILPLLAAS SPEHVALSEE EREEIASVST GSAFVSEYSV PQDLNHELQE QEGEPVPPSN VEAIAEHAVL SEEENEEFEA YSPAAAPTSE SSLSPSTTEK TSENQSPLFS TVTPEYMVLS GDEASESGCY TPDSTSASEY SVPSLATKES LKKTIDRKSP LILKGVSEYM IPSEEKEDTG SFTPAVAPAS EPSLSPSTTE KTSECQSPLP STATSEHVVP SEGEDLGSER FTPDSKLISK YAAPLNATQE SQKKIINEAS QFKPKGISEH TVLSVDGKEV IGPSSPDLVV ASEHSFPPHT TEMTSECQAP PLSATPSEYV VLSDEEAVEL ERYTPSSTSA SEFSVPPYAT PEAQEEEIVH RSLNLKGASS PMNLSEEDQE DIGPFSPDSA FVSEFSFPPY ATQEAEKREF ECDSPICLTS PSEHTILSDE DTEEAELFSP DSASQVSIPP FRISETEKNE LEPDSLLTAV SASGYSCFSE ADEEDIGSTA ATPVSEQFSS SQKQKAETFP LMSPLEDLSL PPSTDKSEKA EIKPEIPTTS TSVSEYLILA QKQKTQAYLE PESEDLIPSH LTSEVEKGER EASSSVAAIP AALPAQSSIV KEETKPASPH SVLPDSVPAI KKEQEPTAAL TLKAADEQMA LSKVRKEEIV PDSQEATAHV SQDQKMEPQP PNVPESEMKY SVLPDMVDEP KKGVKPKLVL NVTSELEQRK LSKNEPEVIK PYSPLKETSL SGPEALSAVK MEMKHDSKIT TTPIVLHSAS SGVEKQVEHG PPALAFSALS EEIKKEIEPS SSTTTASVTK LDSNLTRAVK EEIPTDSSLI TPVDRPVLTK VGKGELGSGL PPLVTSADEH SVLAEEDKVA IKGASPIETS SKHLAWSEAE KEIKFDSLPS VSSIAEHSVL SEVEAKEVKA GLPVIKTSSS QHSDKSEEAR VEDKQDLLFS TVCDSERLVS SQKKSLMSTS EVLEPEHELP LSLWGEIKKK ETELPSSQNV SPASKHIIPK GKDEETASSS PELENLASGL APTLLLLSDD KNKPAVEVSS TAQGDFPSEK QDVALAELSL EPEKKDKPHQ PLELPNAGSE FSSDLGRQSG SIGTKQAKSP ITETEDSVLE KGPAELRSRE GKEENRELCA SSTMPAISEL SSLLREESQN EEIKPFSPKI ISLESKEPPA SVAEGGNPEE FQPFTFSLKG LSEEVSHPAD FKKGGNQEIG PLPPTGNLKA QVMGDILDKL SEETGHPNSS QVLQSITEPS KIAPSDLLVE QKKTEKALHS DQTVKLPDVS TSSEDKQDLG IKQFSLMREN LPLEQSKSFM TTKPADVKET KMEEFFISPK DENWMLGKPE NVASQHEQRI AGSVQLDSSS SNELRPGQLK AAVSSKDHTC EVRKQVLPHS AEESHLSSQE AVSALDTSSG NTETLSSKSY SSEEVKLAEE PKSLVLAGNV ERNIAEGKEI HSLMESESLL LEKANTELSW PSKEDSQEKI KLPPERFFQK PVSGLSVEQV KSETISSSVK TAHFPAEGVE PALGNEKEAH RSTPPFPEEK PLEESKMVQS KVIDDADEGK KPSPEVKIPT QRKPISSIHA REPQSPESPE VTQNPPTQPK VAKPDLPEEK GKKGISSFKS WMSSLFFGSS TPDNKVAEQE DLETQPSPSV EKAVTVIDPE GTIPTNFNVA EKPADHSLSE VKLKTADEPR GTLVKSGDGQ NVKEKSMILS NVEDLQQPKF ISEVSREDYG KKEISGDSEE MNINSVVTSA DGENLEIQSY SLIGEKLVME EAKTIVPPHV TDSKRVQKPA IAPPSKWNIS IFKEEPRSDQ KQKSLLSFDV VDKVPQQPKS ASSNFASKNI TKESEKPESI ILPVEESKGS LIDFSEDRLK KEMQNPTSLK ISEEETKLRS VSPTEKKDNL ENRSYTLAEK KVLAEKQNSV APLELRDSNE IGKTQITLGS RSTELKESKA DAMPQHFYQN EDYNERPKII VGSEKEKGEE KENQVYVLSE GKKQQEHQPY SVNVAESMSR ESDISLGHSL GETQSFSLVK ATSVTEKSEA MLAEAHPEIR EAKAVGTQPH PLEESKVLVE KTKTFLPVAL SCRDEIENHS LSQEGNLVLE KSSRDMPDHS EEKEQFRESE LSKGGSVDIT KETVKQGFQE KAVGTQPRPL EESKVLVEKT KTFLPVVLSC HDEIENHSLS QEGNLVLEKS SRDMPDHSEE KEQFKESELW KGGSVDITKE SMKEGFPSKE SERTLARPFD ETKSSETPPY LLSPVKPQTL ASGASPEINA VKKKEMPRSE LTPERHTVHT IQTSKDDTSD VPKQSVLVSK HHLEAAEDTR VKEPLSSAKS NYAQFISNTS ASNADKMVSN KEMPKEPEDT YAKGEDFTVT SKPAGLSEDQ KTAFSIISEG CEILNIHAPA FISSIDQEES EQMQDKLEYL EEKASFKTIP LPDDSETVAC HKTLKSRLED EKVTPLKENK QKETHKTKEE ISTDSETDLS FIQPTIPSEE DYFEKYTLID YNISPDPEKQ KAPQKLNVEE KLSKEVTEET ISFPVSSVES ALEHEYDLVK LDESFYGPEK GHNILSHPET QSQNSADRNV SKDTKRDVDS KSPGMPLFEA EEGVLSRTQI FPTTIKVIDP EFLEEPPALA FLYKDLYEEA VGEKKKEEET ASEGDSVNSE ASFPSRNSDT DDGTGIYFEK YILKDDILHD TSLTQKDQGQ GLEEKRVGKD DSYQPIAAEG EIWGKFGTIC REKSLEEQKG VYGEGESVDH VETVGNVAMQ KKAPITEDVR VATQKISYAV PFEDTHHVLE RADEAGSHGN EVGNASPEVN LNVPVQVSFP EEEFASGATH VQETSLEEPK ILVPPEPSEE RLRNSPVQDE YEFTESLHNE VVPQDILSEE LSSESTPEDV LSQGKESFEH ISENEFASEA EQSTPAEQKE LGSERKEEDQ LSSEVVTEKA QKELKKSQID TYCYTCKCPI SATDKVFGTH KDHEVSTLDT AISAVKVQLA EFLENLQEKS LRIEAFVSEI ESFFNTIEEN CSKNEKRLEE QNEEMMKKVL AQYDEKAQSF EEVKKKKMEF LHEQMVHFLQ SMDTAKDTLE TIVREAEELD EAVFLTSFEE INERLLSAME STASLEKMPA AFSLFEHYDD SSARSDQMLK QVAVPQPPRL EPQEPNSATS TTIAVYWSMN KEDVIDSFQV YCMEEPQDDQ EVNELVEEYR LTVKESYCIF EDLEPDRCYQ VWVMAVNFTG CSLPSERAIF RTAPSTPVIR AEDCTVCWNT ATIRWRPTTP EATETYTLEY CRQHSPEGEG LRSFSGIKGL QLKVNLQPND NYFFYVRAIN AFGTSEQSEA ALISTRGTRF LLLRETAHPA LHISSSGTVI SFGERRRLTE IPSVLGEELP SCGQHYWETT VTDCPAYRLG ICSSSAVQAG ALGQGETSWY MHCSEPQRYT FFYSGIVSDV HVTERPARVG ILLDYNNQRL IFINAESEQL LFIIRHRFNE GVHPAFALEK PGKCTLHLGI EPPDSVRHK
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with CMYA5?
The strongest Open Targets associations for CMYA5 are neurodegenerative disease, PHF-tau measurement, diet measurement, body height and Familial short QT syndrome.
How long is the CMYA5 protein?
The Homo sapiens CMYA5 protein (UniProt Q8N3K9) is 4069 amino acids long.
Browse: Targets: C · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q8N3K9 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q8N3K9 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.